Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis

Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis

Objective/Background: Among patients undergoing allogeneic hematopoietic cell transplant, continuous intravenous (IV) tacrolimus infusion is frequently used for graft-versus-host disease (GvHD) prophylaxis. Twice-daily intermittent IV tacrolimus dosing may confer safety and convenience benefits. Met...

Full description

Bibliographic Details
Main Authors: Hamza Hashmi, Shruti Bhandari, Rohit Kumar, Prashant Tripathi, Jill Blancett Rhodes, Lindsay Figg, Timothy Baize, Maxwell M. Krem, Mohamed Hegazi, Robert Emmons
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Hematology/Oncology and Stem Cell Therapy
Subjects:
Allogeneic hematopoietic cell transplant
Tacrolimus
Graft-versus-host disease
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387620300509

Internet

http://www.sciencedirect.com/science/article/pii/S1658387620300509

Similar Items